|
gptkbp:instanceOf
|
gptkb:factor_Xa_inhibitor
gptkb:anticoagulant
|
|
gptkbp:antidote
|
gptkb:Andexanet_alfa
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2011 (US)
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80–100%
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:chemicalClass
|
oxazolidinone derivative
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Bayer
|
|
gptkbp:discoveredBy
|
gptkb:Bayer_HealthCare
|
|
gptkbp:eliminationHalfLife
|
5–9 hours (young), 11–13 hours (elderly)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
oral suspension
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits factor Xa
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP2J2, CYP-independent)
|
|
gptkbp:patentExpired
|
2024 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
92–95%
|
|
gptkbp:riskFactor
|
increased bleeding with other anticoagulants
not recommended in patients with prosthetic heart valves
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of venous thromboembolism after orthopedic surgery
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Bayer_HealthCare
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rivaroxaban
|